BACKGROUND: Several recently proposed criteria for assessing cognitive disorder require measuring the cognitive domain of visuo-constructional function. The aims of the present study were to develop a new test (Vienna Visuo-constructional Test-VVT) measuring visuo-constructional functions and to determine the reliability and validity of the VVT in patients with mild cognitive impairment (MCI), Parkinson's disease (PD), and Alzheimer's disease (AD). We further examined age and sex effects and the psychometric quality of the VVT. METHODS: The study included 76 healthy controls and 103 patients who were referred to the Department of Neurology, Medical University of Vienna for neurocognitive assessment. An administering and scoring system for the VVT was developed. RESULTS: Internal consistency (Cronbach's alpha) was found to range from 0.82 for the healthy control group to 0.93 for the total patient group. There was no sex effect, but age had a negative effect on VVT performance. The VVT successfully differentiated healthy controls from MCI patients, AD patients, and PD patients, respectively. CONCLUSION: The VVT shows satisfactory validity and reliability and can be administered easily in clinical practice. It constitutes a new measure that can successfully be used to identify visuo-constructional problems in patients with cognitive dysfunction.
BACKGROUND: Several recently proposed criteria for assessing cognitive disorder require measuring the cognitive domain of visuo-constructional function. The aims of the present study were to develop a new test (Vienna Visuo-constructional Test-VVT) measuring visuo-constructional functions and to determine the reliability and validity of the VVT in patients with mild cognitive impairment (MCI), Parkinson's disease (PD), and Alzheimer's disease (AD). We further examined age and sex effects and the psychometric quality of the VVT. METHODS: The study included 76 healthy controls and 103 patients who were referred to the Department of Neurology, Medical University of Vienna for neurocognitive assessment. An administering and scoring system for the VVT was developed. RESULTS: Internal consistency (Cronbach's alpha) was found to range from 0.82 for the healthy control group to 0.93 for the total patient group. There was no sex effect, but age had a negative effect on VVT performance. The VVT successfully differentiated healthy controls from MCI patients, ADpatients, and PDpatients, respectively. CONCLUSION: The VVT shows satisfactory validity and reliability and can be administered easily in clinical practice. It constitutes a new measure that can successfully be used to identify visuo-constructional problems in patients with cognitive dysfunction.
Authors: Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: Catherine C Price; Holly Cunningham; Nicole Coronado; Alana Freedland; Stephanie Cosentino; Dana L Penney; Alfio Penisi; Dawn Bowers; Michael S Okun; David J Libon Journal: Dement Geriatr Cogn Disord Date: 2011-03-10 Impact factor: 2.959
Authors: R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal Journal: Alzheimer Dis Assoc Disord Date: 1997 Impact factor: 2.703
Authors: J M Shon; D Y Lee; E H Seo; B K Sohn; J W Kim; S Y Park; S G Kim; J H Jhoo; J I Woo Journal: Neuroscience Date: 2013-05-11 Impact factor: 3.590
Authors: R F Zec; E S Landreth; S K Vicari; J Belman; E Feldman; A Andrise; R Robbs; R Becker; V Kumar Journal: Alzheimer Dis Assoc Disord Date: 1992 Impact factor: 2.703
Authors: Tandis Parvizi; Theresa König; Raphael Wurm; Sara Silvaieh; Patrick Altmann; Sigrid Klotz; Paulus Stefan Rommer; Julia Furtner; Günther Regelsberger; Johann Lehrner; Tatjana Traub-Weidinger; Ellen Gelpi; Elisabeth Stögmann Journal: Front Aging Neurosci Date: 2022-08-22 Impact factor: 5.702